Small Molecule uPAR Recruiters for Selective Cancer Cell Destruction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, such as radiation therapy and chemotherapy, are limited in effectiveness for late-stage cancers and associated with significant side effects, necessitating the development of novel strategies that can selectively target cancer cells with reduced toxicity.
Innovation Solution
The design of high-affinity small molecule compounds, like ARM-U2, that bind to the urokinase-type plasminogen activator receptor (uPAR) on cancer cells, recruiting endogenous antibodies for immune-mediated destruction through mechanisms like antibody-dependent cellular phagocytosis and cytotoxicity, without the need for uPA protein administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional cancer treatments (radiation therapy and chemotherapy) are used, then cancer cells can be treated, but significant side effects and limited effectiveness in late-stage cancers occur
Solution Approach 1:
The invention segments the therapeutic approach by using a small molecule compound that specifically targets uPAR on cancer cells, separating the treatment effect from healthy cells. This segmentation allows selective destruction of cancer cells while sparing healthy tissue, thereby reducing side effects while maintaining effectiveness against late-stage cancers.
Solution Approach 2:
The small molecule compound acts as an intermediary that bridges the gap between traditional chemotherapy and immunotherapy. It recruits endogenous antibodies to the cancer cell surface, creating a mediated immune response that is more effective and less toxic than conventional treatments for late-stage cancer.
2Measurement precision
If uPA protein is used to target uPAR, then high-affinity binding is achieved, but stability in vivo is limited and administration limitations occur
Solution Approach 1:
Instead of using the complex uPA protein, the invention creates a simplified copy or mimic - a small molecule compound that replicates the essential binding function. This small molecule copy maintains high binding affinity for uPAR while achieving the stability and administrability that the protein lacks.
Solution Approach 2:
The invention changes the physical and chemical parameters of the targeting agent from a large protein (uPA) to a small molecule structure. This parameter change dramatically improves stability in vivo and ease of administration while preserving the critical binding affinity parameter through rational drug design.
3Ease of manufacture
If small molecule compounds are designed to bind uPAR, then selective targeting of cancer cells is achieved, but development of novel strategies is required
Solution Approach 1:
The small molecule compound serves multiple functions: it directly inhibits uPAR-mediated cancer cell invasion and migration, and simultaneously recruits endogenous antibodies to mediate immune cell destruction. This multi-functionality achieves selective targeting while leveraging existing immune mechanisms, reducing the need for entirely novel complex strategies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
ARM-U2 compounds demonstrate potent efficacy against metastatic cancer cells by inhibiting tumor formation and inducing cancer cell death, offering a therapeutic advance with reduced side effects and improved targeting specificity.
Implementation Method 1
The compounds bind to the urokinase-type plasminogen activator receptor (uPAR) on the surface of a cancer cell, including a metastatic cancer cell, and consequently recruit native antibodies of the patient or subject
Implementation Method 2
antibodies can selectively remove, destroy, clear and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis (ADCP), antibody-dependent cellular cytotoxicity (ADCC)
Data Source
AI summary
The present invention relates to chimeric (including bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic cancer where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds bind to the urokinase-type plasminogen activator receptor (uPAR) on the surface of a cancer cell, including a metastatic cancer cell, and consequently recruit native antibodies of the patient or subject where the antibodies can selectively degrade and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) against a large number and variety of cancers, thus providing cancer cell death and an inhibition of growth, elaboration and/or metastasis of the cancer, including remission and cure of the patient's cancer.